NCT07010588View on ClinicalTrials.gov

Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk

NANot yet recruitingINTERVENTIONAL
Enrollment

1,389

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2030

Conditions
Hepatocellular Carcinoma (HCC)Magnetic Resonance Imaging (MRI)Randomized Controlled Trial
Interventions
DEVICE

non-contrast abbreviated MRI (NC-AMRI)

Non-contrast abbreviated MRI (NC-AMRI) examination include T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI), which takes 10 minutes approximately.

DEVICE

enhanced abbreviated MRI (E-AMRI)

E-AMRI examination (using gadoxetic acid disodium) including T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI)and hepatobiliary phase (HBP) images, which takes 15 minutes approximately.

Trial Locations (12)

100081

Peking University People's Hospital, Beijing

Unknown

The First Affiliated Hospital of Army Medical University, Chongqing

Handan Central Hospital, Handan

Harbin Medical University Cancer Hospital, Harbin

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

China-Japan Union Hospital, Jilin University, Changchun

The Second Hospital of Jilin University, Changchun

Qilu Hospital of Shandong University, Jinan

The Affiliated Hospital of Qingdao University, Qingdao

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an

Tianjin Second People's Hospital, Tianjin

People's Hospital of Xishuangbanna Dai Autonomous Prefecture, Xishuangbanna Dai Autonomous Prefecture

All Listed Sponsors
collaborator

National Research Institute for Family Planning

UNKNOWN

lead

Peking University People's Hospital

OTHER

NCT07010588 - Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk | Biotech Hunter | Biotech Hunter